BioStem Technologies (BioStem Technologies) Cash-to-Debt : 0.02 (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioStem Technologies's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.02.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, BioStem Technologies couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for BioStem Technologies's Cash-to-Debt or its related term are showing as below:

BSEM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 10.44
Current: 0.02

During the past 13 years, BioStem Technologies's highest Cash to Debt Ratio was 10.44. The lowest was 0.02. And the median was 0.06.

BSEM's Cash-to-Debt is ranked worse than
98.44% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs BSEM: 0.02

BioStem Technologies Cash-to-Debt Historical Data

The historical data trend for BioStem Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioStem Technologies Cash-to-Debt Chart

BioStem Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.23

0.03

0.02

0.07

0.15

BioStem Technologies Quarterly Data
	Sep15	Dec15	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	N/A	0.15	0.03	0.02

Competitive Comparison of BioStem Technologies's Cash-to-Debt

For the Biotechnology subindustry, BioStem Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Cash-to-Debt falls into.

BioStem Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioStem Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.772	/	(4.051	+	1.038)
	=	0.15

BioStem Technologies's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.11	/	(4.613	+	1.41)
	=	0.02

BioStem Technologies (OTCPK:BSEM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioStem Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioStem Technologies (BioStem Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website

https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.